Vol 94, No 4 (2023)
Research paper
Published online: 2022-03-03

open access

Page views 2387
Article views/downloads 599
Get Citation

Connect on Social Media

Connect on Social Media

The importance of β-hCG values in prediction of the effectiveness of single dose methotrexate therapy in tubal ectopic pregnancy

Askın Yıldız1, Oznur Bilge2
Pubmed: 35315015
Ginekol Pol 2023;94(4):303-308.

Abstract

Objectives: To investigate the importance of β-hCG values on the day of onset and on the fourth and seventh day after treatment in the effectiveness of treatment in tubal ectopic pregnancies treated with a single dose of methotrexate (MTX).
Material and methods: One hundred sixty-two patients with tubal ectopic pregnancy treated with a single dose MTX treatment were retrospectively evaluated. β-hCG values and changes on Days 0, 4 and 7 of the MTX treatment successful group and the unsuccessful group were analyzed.
Results: MTX treatment was successful in 125 (77.2%) and unsuccessful in 37. When the β-hCG values on Days 0, 4 and 7 were compared in pairs, the differences between groups were statistically significant (p < 0.001). The mean β-hCG value was 783.0 in the MTX successful group and 1802.0 in unsuccessful group (p < 0.001). There was a 21.6% decrease in β-hCG values between Days 0 and day 4 in the MTX successful group and a 25.7% increase in the MTX unsuccessful group (p < 0.001). On Days 0, 4 and 7, ROC curve analysis’s values are , respectively; 755/939/486 for cut off, 86.49/83.78/94.59% for sensitivity and 48.80/69.60/72.36% for specificity.
Conclusions: Success rates of single-dose MTX treatment increase in tubal ectopic pregnancies with low initial β-hCG value. Patients with a decrease in β-hCG value and/or a cut-off decrease of 20% or more on the fourth day of treatment can be called for weekly β-hCG monitoring without the need for close follow-up. The change in β-hCG between Day 0 and Day 4 can be used to predict the efficacy of treatment.

Article available in PDF format

View PDF Download PDF file

References

  1. Bouyer J, Coste J, Fernandez H, et al. Sites of ectopic pregnancy: a 10 year population-based study of 1800 cases. Hum Reprod. 2002; 17(12): 3224–3230.
  2. Lozeau AM, Potter B. Diagnosis and management of ectopic pregnancy. Am Fam Physician. 2005; 72(9): 1707–1714.
  3. Özer M, Alan Y, Doğan A, et al. Tubal Ectopic Pregnancy: Effect of ß-hCG Change in Treatment. International Journal of Gynecological and Obstetrical Research. 2019; 7(1): 1–9.
  4. Lipscomb GH, Givens VM, Meyer NL, et al. Previous ectopic pregnancy as a predictor of failure of systemic methotrexate therapy. Fertil Steril. 2004; 81(5): 1221–1224.
  5. Barnhart KT, Gosman G, Ashby R, et al. The medical management of ectopic pregnancy: a meta-analysis comparing "single dose" and "multidose" regimens. Obstet Gynecol. 2003; 101(4): 778–784.
  6. Farquhar CM. Ectopic pregnancy. The Lancet. 2005; 366(9485): 583–591.
  7. Surampudi K, Gundabattula SR. The role of serum beta hCG in early diagnosis and management strategy of ectopic pregnancy. J Clin Diagn Res. 2016; 10(7): QC08–QC10.
  8. Seeber BE, Barnhart KT. Suspected ectopic pregnancy. Obstet Gynecol. 2006; 107(2 Pt 1): 399–413.
  9. Mol F, Mol BW, Ankum WM, et al. Current evidence on surgery, systemic methotrexate and expectant management in the treatment of tubal ectopic pregnancy: a systematic review and meta-analysis. Hum Reprod Update. 2008; 14(4): 309–319.
  10. Dogan A, Gulhan I, Uyar I, et al. Methotrexate treatment in progressive tubal ectopic pregnancies and hCG-related clinicosurgical implications. Kaohsiung J Med Sci. 2016; 32(6): 317–322.
  11. Saadati N, Najafian M, Masihi S, et al. Comparison of two different protocols of methotrexate therapy in medical management of ectopic pregnancy. Iran Red Crescent Med J. 2015; 17(12): e20147.
  12. Lipscomb GH, Bran D, McCord ML, et al. Analysis of three hundred fifteen ectopic pregnancies treated with single-dose methotrexate. Am J Obstet Gynecol. 1998; 178(6): 1354–1358.
  13. Rodrigues SP, de Burlet KJ, Hiemstra E, et al. Ectopic pregnancy: when is expectant management safe? Gynecol Surg. 2012; 9(4): 421–426.
  14. Menon S, Colins J, Barnhart KT. Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review. Fertil Steril. 2007; 87(3): 481–484.
  15. Tawfiq A, Agameya AF, Claman P. Predictors of treatment failure for ectopic pregnancy treated with single-dose methotrexate. Fertility and Sterility. 2000; 74(5): 877–880.
  16. Celik E, Türkçüoğlu I, Karaer A, et al. Assessment of early decline in the percentage of β-hCG values between days 0 and 4 after methotrexate therapy in ectopic pregnancy for the prediction of treatment success. J Turk Ger Gynecol Assoc. 2013; 14(3): 125–129.
  17. Nowak-Markwitz E, Michalak M, Olejnik M, et al. Cutoff value of human chorionic gonadotropin in relation to the number of methotrexate cycles in the successful treatment of ectopic pregnancy. Fertil Steril. 2009; 92(4): 1203–1207.
  18. Hajenius PJ, Mol BW, Bossuyt PM, et al. Interventions for tubal ectopic pregnancy. Cochrane Database Syst Rev. 2000(2): CD000324.
  19. Fernandez H, Yves Vincent SC, Pauthier S, et al. Randomized trial of conservative laparoscopic treatment and methotrexate administration in ectopic pregnancy and subsequent fertility. Hum Reprod. 1998; 13(11): 3239–3243.
  20. Lipscomb GH, Stovall TG, Ling FW. Nonsurgical treatment of ectopic pregnancy. N Engl J Med. 2000; 343(18): 1325–1329.
  21. Lopez HB, Micheelsen U, Berendtsen H, et al. Ectopic pregnancy and its associated endometrial changes. Gynecol Obstet Invest. 1994; 38(2): 104–106.
  22. Stovall T, Ling F. Single-dose methotrexate: an expanded clinical trial. American Journal of Obstetrics and Gynecology. 1993; 168(6): 1759–1765.
  23. Olofsson JI, Poromaa IS, Ottander U, et al. Clinical and pregnancy outcome following ectopic pregnancy; a prospective study comparing expectancy, surgery and systemic methotrexate treatment. Acta Obstet Gynecol Scand. 2001; 80(8): 744–749.
  24. Stika C, Anderson L, Frederiksen M. Single-dose methotrexate for the treatment of ectopic pregnancy: Northwestern Memorial Hospital three-year experience. American Journal of Obstetrics and Gynecology. 1996; 174(6): 1840–1848.
  25. Alleyassin A, Khademi A, Aghahosseini M, et al. Comparison of success rates in the medical management of ectopic pregnancy with single-dose and multiple-dose administration of methotrexate: a prospective, randomized clinical trial. Fertil Steril. 2006; 85(6): 1661–1666.
  26. Gabbur N, Sherer DM, Hellmann M, et al. Do serum beta-human chorionic gonadotropin levels on day 4 following methotrexate treatment of patients with ectopic pregnancy predict successful single-dose therapy? Am J Perinatol. 2006; 23(3): 193–196.
  27. Nguyen Q, Kapitz M, Downes K, et al. Are early human chorionic gonadotropin levels after methotrexate therapy a predictor of response in ectopic pregnancy? Am J Obstet Gynecol. 2010; 202(6): 630.e1–630.e5.
  28. Skubisz MM, Li J, Lee J, et al. Decline in βhCG levels between days 0 and 4 after a single dose of methotrexate for ectopic pregnancy predicts treatment success: a retrospective cohort study. BJOG. 2011; 118(13): 1665–1668.
  29. Ustunyurt E, Duran M, Coskun E, et al. Role of initial and day 4 human chorionic gonadotropin levels in predicting the outcome of single-dose methotrexate treatment in women with tubal ectopic pregnancy. Arch Gynecol Obstet. 2013; 288(5): 1149–1152.
  30. Agostini A, Blanc K, Ronda I, et al. Prognostic value of human chorionic gonadotropin changes after methotrexate injection for ectopic pregnancy. Fertility and Sterility. 2007; 88(2): 504–506.